If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Models of ideal materials have shown that this zone of plasticity is centered at the crack tip. This equation gives the approximate ideal radius of the plastic zone deformation beyond the crack tip, which is useful to many structural scientists because it gives a good estimate of how the material behaves when subjected to stress. In the above equation, the parameters of the stress intensity factor and indicator of material toughness,
The 5 body regions are right upper, left upper, right lower, left lower, and axial. The Widespread Pain Index (WPI) was introduced by the American College of Rheumatology in 2010. It measures the number of body regions experiencing pain, out of a total of 19: left and right shoulder girdle, upper arm, lower arm, hip/buttock/trochanter, upper leg, lower leg, and jaw; plus the chest, abdomen, neck, upper back and lower back. The Symptom Severity Scale (SSS) assesses the severity of six symptoms; fatigue (score 0-3, for no problem, mild, moderate and severe), trouble thinking or remembering (0-3), waking up tired (unrefreshed) (0-3), pain or cramps in lower abdomen (0-1), depression (0-1) and headache (0-1). As of 2022, among diagnosis methods in the US, the ACR 2016 criteria have been judged as the best FM diagnosis criteria available. The UK RCP also recommends these criteria for FM diagnosis. A similar diagnostic approach is taken in Germany.In 2019, the American Pain Society in collaboration with the U.S. Food and Drug Administration developed a new diagnostic system using two dimensions. The first dimension included core diagnostic criteria, and the second included common features. The core diagnostic criteria are:
The protein tropomyosin covers the myosin-binding sites of the actin molecules in the muscle cell. For a muscle cell to contract, tropomyosin must be moved to uncover the binding sites on the actin. Calcium ions bind with troponin C molecules (which are dispersed throughout the tropomyosin protein) and alter the structure of the tropomyosin, forcing it to reveal the cross-bridge binding site on the actin. The concentration of calcium within muscle cells is controlled by the sarcoplasmic reticulum, a unique form of endoplasmic reticulum in the sarcoplasm. Muscle cells are stimulated when a motor neuron releases the neurotransmitter acetylcholine, which travels across the neuromuscular junction (the synapse between the terminal button of the neuron and the muscle cell). Acetylcholine binds to a post-synaptic nicotinic acetylcholine receptor. A change in the receptor conformation allows an influx of sodium ions and initiation of a post-synaptic action potential. The action potential then travels along T-tubules (transverse tubules) until it reaches the sarcoplasmic reticulum. Here, the depolarized membrane activates voltage-gated L-type calcium channels, present in the plasma membrane. The L-type calcium channels are in close association with ryanodine receptors present on the sarcoplasmic reticulum. The inward flow of calcium from the L-type calcium channels activates ryanodine receptors to release calcium ions from the sarcoplasmic reticulum. This mechanism is called calcium-induced calcium release (CICR).
Paolo Bertoli (1969–1973) Luigi Raimondi (1973–1975) Corrado Bafile (1976–1980) Pietro Palazzini (1980–1988) Angelo Felici (1988–1995) Alberto Bovone (pro-prefect 1995–1998, prefect 1998) José Saraiva Martins (1998–2008) Angelo Amato (pro-prefect 2008–2010, prefect 2010–2018) Giovanni Angelo Becciu (2018 – 24 September 2020) Marcello Semeraro (2020-present)
== Diagnosis == The diagnosis is generally suspected when patients from certain ethnic groups (see epidemiology) develop anemia, jaundice, and symptoms of hemolysis after challenges from any of the above causes, especially when there is a positive family history. Generally, tests will include:
Sources: en.wikipedia.org
Finasteride/latanoprost/minoxidil (developmental code name TH-07 or TH07) is a topical combination drug which is under development for the treatment of alopecia (hair loss). It is specifically a combination of finasteride (Propecia) (0.1%), a 5α-reductase inhibitor (5α-RI); latanoprost (Xalatan) (0.03%), a prostaglandin F2α analogue and prostaglandin F receptor agonist; and minoxidil (Rogaine) (5%), a KATP potassium channel opener. All three of these drugs have individually been shown to stimulate hair growth in the setting of alopecia, and both finasteride and minoxidil are approved and widely used for treatment of alopecia. Finasteride/latanoprost/minoxidil is under development by Triple Hair. As of December 2023, the drug is in phase 2 clinical trials.
West Coast sites replaced the steel lattice towers with simpler guy-stayed masts, although they retained the same wooden towers for reception. East Coast sites had transmitter and receiver blocks protected with earth mounds and blast walls, along with separate reserve transmitter and receivers in small bunkers with attached 120 ft aerial masts. These reserves were in close proximity to the respective transmitter/receiver sites, often in a neighbouring field. West Coast sites relied on site dispersal for protection, duplicating the entire transmitter and receiver buildings.
Official site of the federal government Official tourism site Germany from BBC News Germany. The World Factbook. Central Intelligence Agency. Germany from the OECD Germany at the EU Geographic data related to Germany at OpenStreetMap
=== Resistance === Despite flucloxacillin being insensitive to beta-lactamases, some organisms have developed resistance to it and other narrow-spectrum β-lactam antibiotics including methicillin. Such organisms include methicillin-resistant Staphylococcus aureus, which has developed resistance to flucloxacillin and other penicillins by having an altered penicillin-binding protein.
DELs are subjected to affinity selection procedures on an immobilized target protein of choice, after which non-binders are removed by washing steps, and binders can subsequently be amplified by polymerase chain reaction (PCR) and identified by virtue of their DNA code (e.g.by DNA sequencing). In evolution-based DEL technologies hits can be further enriched by performing rounds of selection, PCR amplification and translation in analogy to biological display systems such as antibody phage display. This makes it possible to work with much larger libraries.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.